9.26
前日終値:
$9.54
開ける:
$9.54
24時間の取引高:
87,723
Relative Volume:
2.63
時価総額:
$121.72M
収益:
-
当期純損益:
$-8.89M
株価収益率:
-13.23
EPS:
-0.7
ネットキャッシュフロー:
$-6.48M
1週間 パフォーマンス:
-13.05%
1か月 パフォーマンス:
-24.22%
6か月 パフォーマンス:
-33.19%
1年 パフォーマンス:
-51.37%
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
名前
Greenwich Lifesciences Inc
セクター
電話
203-434-3290
住所
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
GLSI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
GLSI
Greenwich Lifesciences Inc
|
9.26 | 121.72M | 0 | -8.89M | -6.48M | -0.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-09-01 | 開始されました | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc (GLSI) 最新ニュース
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times
Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener
Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan
Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st
Greenwich LifeSciences Delays Yearly Report Filing - TipRanks
How To Trade (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire
Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com
GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com
Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN
Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com
Greenwich LifeSciences reports positive safety data on GLSI-100 - Investing.com India
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 - GlobeNewswire
Greenwich's Breast Cancer Drug Proves Safe in Phase III Trial, Building on 80% Recurrence Reduction - StockTitan
Trading (GLSI) With Integrated Risk Controls - news.stocktradersdaily.com
Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment - openPR
55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently - Yahoo Finance
Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1% - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verra Mobility Corporation (NASDAQ: VRRM) - PR Newswire
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat
HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat
What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World
Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire
Walmart (NYSE:WMT) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK
Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha
(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com
Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe - GlobeNewswire
Major Breakthrough: Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland - GlobeNewswire
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences gains after GP2 commercial manufacturing update - MSN
Barclays PLC Has $123,000 Stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Bullish Greenwich LifeSciences Insiders Loaded Up On US$3.39m Of Stock - Yahoo Finance
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 - GlobeNewswire
Harvard, Johns Hopkins Join Greenwich LifeSciences' Phase III Breast Cancer Vaccine Trial - StockTitan
Greenwich Lifesciences Inc (GLSI) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):